Dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis).
Peptigrity tracks Survodutide across 219 shops with 25 independent lab tests and an average HPLC purity of 99.59%.
Dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis).
Every submitted test helps the community verify purity across brands. Free, fast, independent.